Black Diamond Therapeutics Future Growth
Future criteria checks 0/6
Black Diamond Therapeutics is forecast to grow earnings and revenue by 5.1% and 67.1% per annum respectively while EPS is expected to grow by 13.3% per annum.
Key information
5.1%
Earnings growth rate
13.3%
EPS growth rate
| Biotechs earnings growth | 27.3% |
| Revenue growth rate | 67.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 13 Jan 2025 |
Recent future growth updates
Recent updates
Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts
Dec 30We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Oct 30
Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
Oct 08Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive
Jun 27Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 21We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 31Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM
Jan 12Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Oct 26Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Deliver On Growth Plans?
May 05We're Keeping An Eye On Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Jan 16Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth?
Oct 02Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
Jul 02We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully
Jan 16We're Hopeful That Black Diamond Therapeutics (NASDAQ:BDTX) Will Use Its Cash Wisely
Jun 11Black Diamond Therapeutics EPS misses by $0.16
May 07We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate
Feb 26What You Need To Know About Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Investor Composition
Jan 05Have Insiders Been Buying Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares?
Dec 01
Black Diamond nominates development candidate for glioblastoma program
Nov 20Black Diamond Therapeutics EPS beats by $0.02
Nov 10Black Diamond Therapeutics: One To Watch In Precision Oncology Space
Oct 23Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 24 | -139 | -179 | -123 | 6 |
| 12/31/2026 | 3 | -113 | -116 | -97 | 6 |
| 12/31/2025 | N/A | -82 | -53 | -69 | 7 |
| 12/31/2024 | N/A | -71 | -66 | -63 | 7 |
| 9/30/2024 | N/A | -73 | -61 | -61 | N/A |
| 6/30/2024 | N/A | -81 | -68 | -68 | N/A |
| 3/31/2024 | N/A | -80 | -68 | -68 | N/A |
| 12/31/2023 | N/A | -82 | -67 | -67 | N/A |
| 9/30/2023 | N/A | -84 | -75 | -75 | N/A |
| 6/30/2023 | N/A | -83 | -73 | -73 | N/A |
| 3/31/2023 | N/A | -87 | -77 | -77 | N/A |
| 12/31/2022 | N/A | -91 | -85 | -85 | N/A |
| 9/30/2022 | N/A | -96 | -88 | -87 | N/A |
| 6/30/2022 | N/A | -109 | -99 | -97 | N/A |
| 3/31/2022 | N/A | -121 | -107 | -104 | N/A |
| 12/31/2021 | N/A | -126 | -103 | -100 | N/A |
| 9/30/2021 | N/A | -122 | -94 | -92 | N/A |
| 6/30/2021 | N/A | -105 | -78 | -77 | N/A |
| 3/31/2021 | N/A | -85 | -65 | -65 | N/A |
| 12/31/2020 | N/A | -67 | -52 | -52 | N/A |
| 9/30/2020 | N/A | -55 | -44 | -44 | N/A |
| 6/30/2020 | N/A | -46 | -38 | -38 | N/A |
| 3/31/2020 | N/A | -44 | -29 | -29 | N/A |
| 12/31/2019 | N/A | -35 | -25 | -25 | N/A |
| 9/30/2019 | N/A | -28 | -20 | -20 | N/A |
| 6/30/2019 | N/A | -22 | -16 | -16 | N/A |
| 3/31/2019 | N/A | -11 | -13 | -13 | N/A |
| 12/31/2018 | N/A | -9 | -9 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BDTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BDTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BDTX is forecast to have no revenue next year.
High Growth Revenue: BDTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BDTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/03 08:02 |
| End of Day Share Price | 2025/02/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Black Diamond Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Arlinda Lee | Canaccord Genuity |
| Robert Burns | H.C. Wainwright & Co. |